Should chlamydia be retested after treatment?

Test-of-Cure vs. Rescreening: Two Distinct Concepts

A test-of-cure is NOT routinely recommended after chlamydia treatment with doxycycline or azithromycin, but rescreening for reinfection at 3 months IS strongly recommended, especially for women. 1

Test-of-Cure (Early Retesting)

Do NOT perform test-of-cure in the following situations:

• Patients treated with recommended regimens (doxycycline or azithromycin)
• Unless therapeutic compliance is questionable
• Unless symptoms persist
• Unless reinfection is suspected

1

Why Test-of-Cure is Not Recommended

Testing before 3 weeks post-treatment is problematic because:

• False-negative results can occur from small numbers of remaining organisms
• False-positive results are common with NAATs due to continued excretion of dead organisms
• The recommended regimens (doxycycline and azithromycin) have 97-98% efficacy rates

1

Exception: Pregnant Women

Test-of-cure IS recommended for pregnant women at 3-4 weeks after treatment completion, preferably by culture, because:

• Alternative regimens used in pregnancy (erythromycin, amoxicillin) may be less efficacious
• Gastrointestinal side effects of erythromycin may reduce compliance
• The stakes are higher given pregnancy complications

2, 1

Rescreening for Reinfection (3 Months Post-Treatment)

All women with chlamydia should be rescreened approximately 3 months after treatment because:

• High reinfection rates (13.9-20% within 8-10 months) 3
• Most post-treatment infections are reinfections, not treatment failures
• Repeat infections confer elevated risk for PID and complications compared to initial infection
• Partners often remain untreated or patients return to high-prevalence sexual networks

1

Specific Rescreening Recommendations

Women (highest priority):

• Rescreen at 3 months after treatment 1
• Rescreen whenever they present for care within 3-12 months, regardless of whether partners were treated 1
• Adolescent women are especially high priority 2

Men:

• Limited evidence exists, but some specialists suggest rescreening at approximately 3 months 1

Timing Considerations

The optimal retest interval appears to be 8 weeks based on research showing:

• Higher uptake at 8 weeks (77%) compared to 16 weeks (67%) or 26 weeks (64%)
• Similar positivity rates across all timeframes
• Peak reinfection rates occur at 8-10 months

4, 3

Common Pitfalls to Avoid

1. Don't confuse test-of-cure with rescreening - they serve different purposes and occur at different timeframes
2. Don't test before 3 weeks - high risk of false results with NAATs
3. Don't skip rescreening in women - this is about detecting reinfection to prevent PID, not verifying treatment success
4. Don't assume partner treatment occurred - rescreen regardless of patient's belief about partner treatment 1

Clinical Algorithm

At time of diagnosis:

• Treat with doxycycline 100mg BID × 7 days or azithromycin 1g single dose
• Instruct abstinence for 7 days after single-dose or until completion of 7-day regimen
• Ensure partner notification and treatment
• Schedule 3-month rescreening appointment (especially for women)

At 3 months:

• Retest all women
• Consider retesting men
• This detects reinfection, not treatment failure

Exception - Pregnant women:

• Test-of-cure at 3-4 weeks after treatment completion
• Use culture if available